These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21178990)

  • 1. Application of the BRAT framework to case studies: observations and insights.
    Levitan BS; Andrews EB; Gilsenan A; Ferguson J; Noel RA; Coplan PM; Mussen F
    Clin Pharmacol Ther; 2011 Feb; 89(2):217-24. PubMed ID: 21178990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Framework for use of toxicity screening tools in context-based decision-making.
    Doull J; Borzelleca JF; Becker R; Daston G; DeSesso J; Fan A; Fenner-Crisp P; Holsapple M; Holson J; Craig Llewellyn G; MacGregor J; Seed J; Walls I; Woo YT; Olin S
    Food Chem Toxicol; 2007 May; 45(5):759-96. PubMed ID: 17215066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Triptans--pivotal event in migraine treatment].
    Lusić I; Bilić I
    Acta Med Croatica; 2008 May; 62(2):173-8. PubMed ID: 18710081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute migraine treatment with rizatriptan in real world settings - focusing on treatment strategy, effectiveness, and behavior.
    Hu H; Kurth T; Cady R; Santanello N; Bigal ME
    Headache; 2009 Feb; 49 Suppl 1():S34-42. PubMed ID: 19161564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis.
    Garrison LP; Towse A; Bresnahan BW
    Health Aff (Millwood); 2007; 26(3):684-95. PubMed ID: 17485745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
    Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P
    Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frovatriptan: new drug. Migraine attacks: an unnecessary triptan. Less effective than sumatriptan, but more adverse effects.
    Prescrire Int; 2008 Jun; 17(95):106. PubMed ID: 18623914
    [No Abstract]   [Full Text] [Related]  

  • 10. A health outcomes framework for assessing health status and quality of life: enhanced data for decision making.
    Erickson P
    J Natl Cancer Inst Monogr; 2004; (33):168-77. PubMed ID: 15504927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six Sigma: not for the faint of heart.
    Benedetto AR
    Radiol Manage; 2003; 25(2):40-53. PubMed ID: 12800564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute treatment of migraine.
    Tepper SJ; Spears RC
    Neurol Clin; 2009 May; 27(2):417-27. PubMed ID: 19289223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
    Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
    Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A quantitative approach to benefit-risk assessment of medicines - part 2: the practical application of a new model.
    Mussen F; Salek S; Walker S; Phillips L
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S16-41. PubMed ID: 17546574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of adherence to triptans: factors of sustained vs lapsed users.
    Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
    Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathways to the best fit of triptans for migraine patients.
    Buzzi MG
    Cephalalgia; 2008 Sep; 28 Suppl 2():21-7. PubMed ID: 18715329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians.
    Quartey G; Wang J
    Pharm Stat; 2012; 11(1):82-5. PubMed ID: 21997832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives.
    Felli JC; Noel RA; Cavazzoni PA
    Med Decis Making; 2009; 29(1):104-15. PubMed ID: 18812582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptan use as a function of cardiovascular risk. A population-based study.
    Bigal ME; Golden W; Buse D; Chen YT; Lipton RB
    Headache; 2010 Feb; 50(2):256-63. PubMed ID: 20039953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health outcomes evaluations: estimating the impact of almotriptan in managed care settings.
    Mayo KW; Osterhaus JT
    Am J Manag Care; 2002 Feb; 8(3 Suppl):S85-93. PubMed ID: 11859909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.